These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6173558)

  • 41. Interferon and natural killer (NK) cells.
    Herberman RB; Ortaldo JR; Timonen T; Reynolds CW; Djeu JY; Pestka S; Stanton J
    Tex Rep Biol Med; 1981-1982; 41():590-5. PubMed ID: 6189224
    [No Abstract]   [Full Text] [Related]  

  • 42. Enhancement of mouse NK cells by interferon.
    Senik A; Gresser I; Maury C; Gidlund M; Orn A; Wigzell H
    Transplant Proc; 1979 Mar; 11(1):993-6. PubMed ID: 452109
    [No Abstract]   [Full Text] [Related]  

  • 43. Defects of immune interferon secretion and natural killer activity in patients with immunological disorders.
    Virelizier JL; Lipinski M; Tursz T; Griscelli C
    Lancet; 1979 Sep; 2(8144):696-7. PubMed ID: 90787
    [No Abstract]   [Full Text] [Related]  

  • 44. Cellular immunology in multiple sclerosis. A review through 1984.
    Baumhefner RW; Tourtellotte WW
    Concepts Immunopathol; 1985; 2():151-88. PubMed ID: 2439204
    [No Abstract]   [Full Text] [Related]  

  • 45. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.
    Santoli D; Hall W; Kastrukoff L; Lisak RP; Perussia B; Trinchieri G; Koprowski H
    J Immunol; 1981 Apr; 126(4):1274-8. PubMed ID: 6162885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of interferon in the NK cell killing of virus-infected target cells.
    Anderson MJ
    J Hyg (Lond); 1982 Oct; 89(2):347-51. PubMed ID: 6182244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The natural cytotoxicity system in patients with multiple sclerosis: clinico-immunological parallels].
    Cheknev SB; Latysheva OL; Demina TL; Sorokin AM; Gusev EI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(7):16-9. PubMed ID: 2800805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.
    Chan CW; Crafton E; Fan HN; Flook J; Yoshimura K; Skarica M; Brockstedt D; Dubensky TW; Stins MF; Lanier LL; Pardoll DM; Housseau F
    Nat Med; 2006 Feb; 12(2):207-13. PubMed ID: 16444266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Multiple sclerosis; current developments in the pathogenesis and treatment].
    van Lambalgen R; Sanders EA
    Ned Tijdschr Geneeskd; 1984 Sep; 128(35):1669-73. PubMed ID: 6207446
    [No Abstract]   [Full Text] [Related]  

  • 50. Natural cytotoxicity of mouse monocytes and macrophages.
    Tagliabue A; Mantovani A; Kilgallen M; Herberman RB; McCoy JL
    J Immunol; 1979 Jun; 122(6):2363-70. PubMed ID: 221585
    [No Abstract]   [Full Text] [Related]  

  • 51. [Aspects of antiviral immunity in patients with multiple sclerosis].
    Mayer M
    Cas Lek Cesk; 1985 Jul; 124(28):869-71. PubMed ID: 2411404
    [No Abstract]   [Full Text] [Related]  

  • 52. In vitro interactions of purified cloned human interferons on NK cells: enhanced activation.
    Targan S; Stebbing N
    J Immunol; 1982 Sep; 129(3):934-5. PubMed ID: 6180004
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of interferon on human lymphoid cells and their function.
    Heron I; Hokland M; Hokland P; Berg K
    Ann N Y Acad Sci; 1980; 350():112-20. PubMed ID: 6165265
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of various interferons on the spontaneous cytotoxicity exerted by lymphocytes from normal and tumor-bearing patients.
    Lucero MA; Fridman WH; Provost MA; Billardon C; Pouillart P; Dumont J; Falcoff E
    Cancer Res; 1981 Jan; 41(1):294-9. PubMed ID: 6160906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Understanding the role of natural killer cell receptors and their human leukocyte antigen ligands in multiple sclerosis.
    Trachtenberg EA
    Ann Neurol; 2009 Jun; 65(6):626-8. PubMed ID: 19557875
    [No Abstract]   [Full Text] [Related]  

  • 56. Altered natural killer cell response in patients with malignant lymphoma.
    Hawrylowicz CM; Rees RC; Potter CW; Hancock BW
    Philos Trans R Soc Lond B Biol Sci; 1982 Sep; 299(1094):141-4. PubMed ID: 6183691
    [No Abstract]   [Full Text] [Related]  

  • 57. Imatinib mesylate--uncovering a fast track to adaptive immunity.
    Smyth MJ
    N Engl J Med; 2006 May; 354(21):2282-4. PubMed ID: 16723621
    [No Abstract]   [Full Text] [Related]  

  • 58. Effector cell sensitivity to sugar moieties. II. Inhibition by monosaccharides of interferon enhanced human natural killing.
    Ades EW; Hinson A
    J Clin Lab Immunol; 1983 Aug; 11(4):173-6. PubMed ID: 6199501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of natural killer cells and of interferon in natural resistance against virus infections.
    Kirchner H; Engler H; Zawatzky R; Schindler L
    Adv Exp Med Biol; 1982; 155():785-97. PubMed ID: 6186129
    [No Abstract]   [Full Text] [Related]  

  • 60. Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis.
    Abb J; Deinhardt F; Zander H; Tenser RB; Rapp F; Goust JM; Fudenberg HH; Vilcek J; Ho M; Merigan TC; Oldstone MB; Jackson GG
    J Infect Dis; 1982 Jul; 146(1):109-15. PubMed ID: 6177805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.